MONOCLE Trial for patients with CMML (Chronic Myelomonocytic Leukaemia)
The aim of this study is to assess the effectiveness and safety of a new drug, called Tefinostat, for patients with CMML (Chronic Myelomonocytic Leukaemia).
Tefinostat is an oral agent that belongs to a family of drugs called ‘histone deacetylase inhibitors’. Tefinostat only gets converted to its active formulation once it has been absorbed by monocytes; monocytes are the cell type that make up a significant proportion of the leukaemia in the blood and bone marrow of patients with CMML. In the MONOCLE study, CMML patients receive tefinostat treatment for 24 weeks with the option of continuing beyond this initial period if it is bringing about a clinical improvement in their disease.
MONOCLE trial is now closed, we hope to add results when they are available.
For further details of the study, including inclusion and exclusion criteria, visit the Cancer Research UK website.